Electrocore (ECOR) 2026 Earnings: Insights & Outlook
A deep-dive look at electroCore's 2026 earnings narrative. This article unpacks Q1 signals, growth drivers, and pract...
Biotech Stocks
Biotech Stocks page aggregates 6 articles covering catalysts, earnings moves, and company updates to help you spot opportunities and manage biotech investments more confidently.
158 articles
Nurix Therapeutics Insider Moves and Insights for Investors
A Nurix Therapeutics insider recently sold shares, drawing attention from investors. This article breaks down the mov...
Crinetics Director Sells 5,000 Shares: Key Takeaways
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
Ligand Pharma Sells $688K: CFO Stock Sale Spotlight
When a company's CFO divests shares amid a strong stock run, investors want to know what it means. This deep dive exp...
Lenz Therapeutics Stock Plummeted This Week: Why It Happened
This week brought a sharp decline in lenz therapeutics stock plummeted as concerns about revenue growth and financing...
Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Celcuity Stock Popped Today: Key Drivers Behind the Jump
Celcuity stock popped today after the company released its 2025 results, showing a tighter quarterly loss despite no ...
Erasca CMO's Direct Stake Goes to Zero: Investor Implications
When a company's top medical officer sells a large block and leaves with a zero direct stake, investors notice. This ...
Stock Market Today, March: Wave Life Dives After Data Disappoints
A biotech name drops sharply after mixed obesity data, sending Wave Life Sciences and the broader market into a brief...
Barclays Thinks Ionis Headed Toward a $106 Target This Year
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Cytosorbents (CTSO) 2025 Earnings Outlook for Investors
Investors are weighing the beads-and-blood-screening company Cytosorbents as it reports 2025 earnings. This guide bre...
Lucid Diagnostics (LUCD) Earnings: Outlook and Analysis
Lucid Diagnostics (LUCD) is navigating reimbursement and adoption as it scales its non-invasive tests. This analysis ...
Related Topics
#Investing (126)
#Stock Analysis (39)
#Earnings Analysis (28)
#Insider Trading (22)
#Stock Market (16)
#Stock Market News (16)
#Earnings (14)
#Portfolio Strategy (12)
#Portfolio Management (11)
#Investing Strategy (9)
#SEC Filings (7)
#risk-management (6)
#Hedge Funds (6)
#CRISPR (6)
#Pharmaceuticals (5)